ArticleFrontiers in endocrinology2026
Integrated RNA-seq and sQTL analysis reveal immune and splicing regulatory features underlying relapse and remission after treatment of Graves' disease.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Graves' disease (GD) is a classical autoimmune disorder caused by interactions between genetic susceptibility and immune dysregulation. However, the transcriptomic mechanisms underlying disease relapse and remission, particularly those involving alternative splicing (AS), remain poorly understood. Methods: We performed an integrative RNA-seq analysis of peripheral blood samples from 33 GD patients in remission, 31 GD patients in relapse, and 30 normal controls (NC). Gene expression, transcript usage, alternative splicing events (ASEs), RNA-binding protein (RBP) regulation, and splicing quantitative trait loci (sQTLs) were systematically analyzed to characterize transcriptomic alterations associated with different disease states. Results: Compared with NC, relapse-associated differentially expressed genes (DEGs) were mainly enriched in antimicrobial humoral immunity and suppression of TNF signaling, whereas remission-associated DEGs were associated with metabolic homeostasis and apoptosis regulation. Notably, 74 DEGs were consistently upregulated in both disease states. Transcriptomic analysis identified 234,595 transcripts, including 17.1% novel isoforms, and detected 352 and 387 differentially expressed transcripts (DETs) in relapse and remission, respectively. Transcript-level alterations frequently occurred independently of gene-level expression changes, indicating extensive isoform-specific regulation, as exemplified by isoform switching of Discussion: These findings demonstrate that GD relapse and remission are closely associated with genetically and RBP-mediated alternative splicing regulation. Our study provides new insights into the molecular mechanisms underlying immune imbalance in GD and highlights potential transcriptomic biomarkers associated with disease relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.